Reasons for performing study: Cardiac output does not always increase with dobutamine administration in anaesthetised horses and information on peripheral perfusion is lacking. Objectives: To determine the effect of intravenous (i.v.) dobutamine infusion with and without a concurrent 20 mL/kg bodyweight (bwt) bolus of crystalloid fluids on the cardiovascular function of acepromazine premedicated, hypotensive, isoflurane-anaesthetised horses. Study design: Randomised, cross-over experiment. Methods: A total of 6 horses aged 5-13 years, weighing 464-578 kg were premedicated with acepromazine 0.02 mg/kg bwt and then sedated with xylazine 0.8 mg/kg bwt i.v. Anaesthesia was induced with ketamine 2.2 mg/kg bwt and diazepam 0.08 mg/kg bwt i.v. and maintained with isoflurane, adjusted to achieve a target mean arterial pressure (MAP) (60 mmHg AE 5%) 60 min post-induction of anaesthesia (T0). One of 2 treatments was then given. In treatment D, dobutamine was initially infused at 0.5 lg/kg bwt/min and adjusted to achieve a target MAP (80 mmHg AE 5%) within 30 min of infusion initiation. In treatment D+F dobutamine was administered as described for treatment D, with 20 mL/kg bwt Hartmann's solution infused i.v. over 20 min. Cardiac index (CI), haemoglobin concentration ([Hb]), arterial oxygen content (CaO 2 ), oxygen delivery index (DO 2 I) and bilateral femoral arterial blood flow (FBF) were recorded at T0, 30 min following dobutamine initiation (T1) and 15 min following dobutamine cessation (T2). Data were analysed using a mixed-effect linear model (P<0.05 considered significant). Results: A significant increase in DO 2 I (P = 0.008, T0/T1), CaO 2 (P = 0.0002, T0/T1) and [Hb] (P<0.0001, T0/T1) and in CaO 2 (P = 0.0005, T1/T2) and [Hb] (P = 0.002,T1/T2) occurred during treatment D. A significant increase in FBF (P = 0.005, upper limb; P = 0.042 lower limb, T0/T1) occurred during treatment D+F. Significant differences between treatments were recorded at T1 ([Hb] P = 0.0001, CaO 2 P = 0.0003) and T2 ([Hb] P = 0.013). There was no change in CI during either treatment. Conclusions: The increase in FBF seen with co-administration of fluids and dobutamine may provide a beneficial effect on muscle compared with the use of dobutamine alone.
Introduction
Dobutamine is a b1 receptor agonist used to treat hypotension in anaesthetised horses. Initial studies in halothane-anaesthetised horses showed dobutamine administration increased arterial blood pressure (BP) by increasing stroke volume (SV) and thus cardiac output (Qt) [1] . Subsequent studies in anaesthetised horses reported differing cardiovascular responses during dobutamine administration. Although, BP consistently increases during dobutamine administration [2] [3] [4] , increases in Qt are not always observed [2] . In addition when increases in Qt are reported, it has been associated with either an increase in SV [3] or heart rate (HR) [4] . It is possible that the choice of anaesthetic protocol may contribute to the differences in cardiovascular function observed. A recent study in isoflurane-anaesthetised horses premedicated with acepromazine failed to produce a significant increase in Qt with dobutamine administration until the onset of surgical stimulation, with the subsequent increase in Qt associated with a significant increase in HR [5] .
Acepromazine premedication prior to isoflurane anaesthesia is a common combination used in horses [6] . Isoflurane and acepromazine decrease peripheral vascular resistance (PVR), which decreases BP and preload [7] . Reduced preload can reduce the ability of the heart to increase SV and thus Qt in response to dobutamine administration [8] . Concurrent administration of intravenous (i.v.) fluids may improve the effects of dobutamine on Qt in the face of reduced preload. Although there are no studies investigating the concurrent administration of inotropes such as dobutamine and fluids, studies in people undergoing caesarean section with epidural anaesthesia and dogs with haemorrhagic shock have demonstrated improvement in cardiac function and oxygen delivery during concurrent administration of i.v. fluids and vasopressor agents compared with vasopressor agents alone [9, 10] . There is no literature on the use of fluids to treat cardiovascular compromise in healthy anaesthetised horses.
The aim of this study was to determine the effect of i.v. dobutamine infusion with and without a concurrent 20 mL/kg bodyweight (bwt) bolus of crystalloid fluids on the cardiovascular function of healthy, isofluraneanaesthetised horses premedicated with acepromazine. Our hypothesis was that a combination of dobutamine infusion and crystalloids would increase cardiac index (CI), oxygen delivery index (DO 2 I) and femoral arterial blood flow (FBF) above baseline, whereas dobutamine alone would not. It was further hypothesised that horses receiving crystalloids and dobutamine would require a lower rate of dobutamine infusion to achieve target BP than dobutamine alone. It was also hypothesised that administration of dobutamine and crystalloids would result in a persistent increase in DO 2 I, FBF and BP 15 min after dobutamine infusion has been stopped.
Material and methods

Study design
were performed prior to enrolment to ensure the horses were free of heart disease. On the morning of anaesthesia, the horses were assessed as healthy based on clinical examination. Packed cell volume (PCV) and total plasma protein (TPP) were measured to confirm normal hydration. Food was withheld for at least 1 h prior to anaesthesia. Water was withheld from the time of premedication.
Anaesthesia
Each horse was anaesthetised twice, with an interval of at least 3 weeks. Prior to the first anaesthetic, horses were randomly allocated (http:// www.randomizer.org/form.htm) to receive one of 2 treatments. The remaining treatment was administered during the second anaesthetic. 
Data collection
Data were collected at baseline, prior to treatment (T0), at the end of treatment (T1) and 15 min after stopping treatment (T2). Baseline data were recorded 60 min after induction of anaesthesia, after achieving an isoflurane-induced target MAP of 60 mmHg AE 5% and a stable end-tidal isoflurane percentage for ≥15 min. Collection of baseline data 60 min after induction of anaesthesia also ensured that induction agents did not interfere with the technique used for measurement of Qt [11] . After collection of baseline data, each horse received its randomly allocated treatment. Treatment D consisted of dobutamine (250 lg/mL) administered at an initial infusion rate of 0.5 lg/kg bwt/min using an infusion pump (Baxter) c . The infusion rate was subsequently increased by increments of 0.5 lg/kg bwt/min every 5 min as necessary to achieve a target MAP of 80 mmHg AE 5% at 30 min after onset of the infusion. Treatment D+F consisted of dobutamine administered as described for treatment D in conjunction with a 20 mL/kg bwt bolus of Hartmann's solution, infused i.v. during the initial 20 min of the dobutamine infusion. To avoid dilution of the dobutamine during Hartman's administration, the fluids and dobutamine were administered via different venous catheters.
Data collected at each sample time included HR, systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressure, Qt, PCV, TPP, haemoglobin concentration [Hb] , sodium concentration [Na + ] arterial oxygen tension (PaO 2 ), arterial oxygen saturation (SaO 2 ) and FBF in the upper and lower limb. The administered dose of dobutamine required to achieve the target MAP (80 mmHg AE 5%) was recorded.
Cardiac output was determined using the lithium dilution technique [12] . Prior to each Qt determination, the plasma [Na + ] and [Hb] were measured using a bench side blood gas analyser (Vet Scan Istat-1 DRC-300V) n . For each Qt measurement the dobutamine infusion was momentarily stopped while 0.003 mmol/kg lithium chloride o was injected i.v. via the left jugular catheter. At each sample time, 2 Qt measurements were performed within 5 min and the average of the 2 measurements calculated. The percentage difference between duplicate measurements was calculated as ([measurement 1 -measurement 2]/measurement 1) 9 100 [13, 14] .
Femoral arterial blood flow within the dependent and nondependent hindlimb was measured using transcutaneous Doppler ultrasonography (Phillips CX-50) a according to previously published techniques [15] . After completion of data collection at T2, anaesthesia was stopped; horses were recovered in a padded recovery box and then returned to a small paddock for 36 h. Data-sets were all considered continuous and tested for normality using the Shapiro-Wilk test with all data-sets considered normally distributed based on failure to reject the null hypothesis of normality (P>0.05). Normality of the models was confirmed based on QQ plots of the residuals. Data are summarised as mean and 95% confidence interval. Data were tested for a fixed effect of treatment and time using a mixed-effect linear model that also included the random variance of horse across treatment. Where there were significant interactions of treatment and time, or main effects of treatment or time, post-hoc a priori contrasts within and between treatments were made using Tukey's adjustment for multiple comparisons. An adjusted P value ≤0.05 was considered significant and is reported.
Data analysis
The infused dose of dobutamine was compared across treatments using a paired t test with P<0.05 considered significant. Where there were no differences between treatments, sample size estimation for detecting the observed difference between treatments for paired parametric analysis at P<0.05 with a power of 0.8 was calculated. All analyses were performed with standard computer software (SAS version 9.4) p .
Results
Complete data were obtained at T0 and T1 from all 6 horses. Measured and calculated cardiovascular data are summarised in Table 1 . Measured and calculated indices of oxygenation and ventilation are summarised in Table 2 . Data were obtained at T2 from only 4 of the 6 horses receiving treatment D+F. One horse receiving treatment D+F moved 10 min after collection of data at T1, requiring i.v. thiopentone (Ilium Thiopentone) f administration to deepen the plane of anaesthesia. Blood gas results were not available at T2 for one horse receiving treatment D+F due to technical problems and thus oxygen delivery could not be calculated. Data collected from T0 and T1 from these horses were included in statistical analysis at T0 and T1. Where data is missing the number of horses used to calculate the mean and 95% confidence intervals are provided in Tables  1 and 2 . A total of 35 paired Qt measurements were recorded during this study. The mean (95% confidence interval) for the difference between duplicate Qt measurements was 5.37% (4.00-6.78%). The mean (95% confidence interval) end-tidal isoflurane percentage required to achieve a target MAP of 60 mmHg AE 5% was 1.6% (1.4-1.8%) for horses receiving treatment D and 1.6% (1.4-1.9%) for horses receiving treatment D+F. The mean (95% confidence interval) dose of dobutamine required to achieve a target MAP of 80 mmHg AE 5% did not differ significantly between treatment D (1.0 [0.67-1.33] lg/kg bwt/min]) and D+F (0.75 [0.13-1.37] lg/kg bwt/min) (P = 0.2).
There was a significant interaction for treatment and time for DO 2 I (P = 0.03). Post-hoc comparisons within treatment D (Table 1) showed DO 2 I significantly increased between T0 and T1 (P = 0.008) and remained higher at T2 but was not significantly different to baseline (P = 0.6). DO 2 I index did not significantly differ within treatment D+F (T0 and T1 P = 0.48; T1 and T2 P = 0.58; T0 and T2 P = 1.0). There was no significant difference for DO 2 I between treatments (P = 0.10). The estimated sample size required to detect a difference between treatments for DO 2 I was >300. There was no significant interaction for treatment and time for CI (P = 0.992) or main effects (treatment P = 0.9, time P = 0.1) indicating no significant change in CI within or between treatments. There was a significant interaction of treatment and time for CaO 2 (P = 0.007) and [Hb] (P = 0.002). Comparisons within treatment D showed CaO 2 and [Hb] significantly increased from T0 to T1 (P = 0.0002, P<0.0001, respectively) and remained significantly increased from baseline at T2 (P = 0.0005, P = 0.002, respectively). During treatment D+F CaO 2 and [Hb] did not significantly change. The CaO 2 and [Hb] were significantly higher for treatment D compared with D+F at T1 (P = 0.0003, P = 0.0001, respectively) and at T2 (P = 0.05, P = 0.01, respectively). There was a significant main effect of time for upper FBF (P = 0.001) and treatment and time for lower FBF (treatment P = 0.01, time P = 0.002). Comparisons within treatment D+F showed FBF in the upper and the lower limbs significantly increased from T0 to T1 (P = 0.005, P = 0.04, respectively). Comparisons within treatment D or between treatments did not show any significant difference in FBF.
Discussion
This study compared the effects of dobutamine administration alone and in combination with a 20 mL/kg bwt Hartmann's solution bolus on cardiovascular function in hypotensive isoflurane-anaesthetised horses, premedicated with acepromazine. Our hypothesis was that a combination of dobutamine infusion and crystalloids would increase CI, DO 2 I and FBF, while dobutamine alone would not. In addition, we proposed a lower rate of dobutamine infusion would be required to achieve target BP with dobutamine infusion and crystalloids than with dobutamine alone. Our results did not completely reject this hypothesis. Results supportive of the research hypothesis were the significant increase in FBF in both limbs during administration of dobutamine and fluids, while administration of dobutamine alone did not. It was also hypothesised that administration of dobutamine and crystalloids would result in a persistent increase in DO 2 I, FBF and BP for 15 min after dobutamine infusion was stopped. The results of this study did not support this research hypothesis.
In our study, end-tidal isoflurane concentration was adjusted to produce a target MAP (60 AE 5% mmHg) prior to treatment. In addition, the rate of dobutamine was adjusted to achieve a target increase in MAP (80 AE 5% mmHg). This contrasts with previous studies that administered dobutamine at a constant rate [2, 3, 16] in normotensive horses [2, 17] . However, the method used in our study was chosen to mimic the clinical setting, where dobutamine is administered to hypotensive horses and the rate of dobutamine administration is adjusted until an increase in MAP is achieved. The dose of dobutamine needed to achieve the required increase in MAP did not differ between treatments and the dose rates required in this study were similar to previous studies [4, 5, [17] [18] [19] .
The significant increase in DO 2 I observed during administration of dobutamine alone was not accompanied by a significant increase in CI. This suggests that the increase in DO 2 I was due to the increase in [Hb] and thus CaO 2 . Increases in [Hb] associated with an increased PCV have been reported after dobutamine administration in halothane-anaesthetised horses [2, 20] and has been attributed to a1 adrenoceptor mediated splenic contraction [21] . Interestingly, the increase in [Hb] during dobutamine administration in the present study occurred despite the administration of acepromazine. Acepromazine has been reported to decrease PCV and thus [Hb] in conscious horses [22] and therefore was expected to offset the effect of dobutamine. The failure to detect any change in DO 2 I during coadministration of fluids and dobutamine parallels the measurements of CI as well as the absence of change in CaO 2 and [Hb]. The concurrent administration of dobutamine and fluids would likely result in haemodilution, obscuring any increase in [Hb] and PCV mediated by dobutamine administration. Interestingly, although the increase in CaO 2 and [Hb] during dobutamine administration alone resulted in a significant difference between treatments, there was no significant difference between treatments for DO 2 I. This may be affected by the magnitude of variance in the face of a small sample size. However, a sample of 300 horses would have been required to declare the difference in DO 2 I significant and thus even a moderate increase in sample size would not have changed the conclusion. Furthermore, the variability in measures of cardiac function observed in our study was comparable [5] and lower [4] than previous related equine anaesthetic studies.
A possible but unlikely reason for lack of significant increase in CI within each horse during each treatment was interference with the measurement of Qt by administration of certain drugs, particularly at baseline. Administration of xylazine has been observed to increase the measured voltage during performance of the lithium dilution technique resulting in an overestimation of Qt. However, this effect is reported to diminish 30 min after xylazine administration [23] . Another study in horses found good agreement between bolus thermodilution and LiDCO Qt measurements 60 min after induction of anaesthesia in horses premedicated with xylazine 0.8 mg/kg bwt i.v. [24] . Thus the impact of the xylazine premedication on LiDCO readings is considered unlikely in this study as data collection was started 60 min after administration of xylazine.
It is also worthy to note, that small but insignificant increase in PaCO2 from baseline were observed during both treatments despite maintaining constant peak inspiratory pressure and RR. The reason for this could not be determined but may reflect changes in lung compliance and delivered tidal volume during the course of the study. As increases in PaCO 2 are reported to stimulate the sympathetic nervous system [25] , this would be expected to increase Qt and thus does not explain the lack of significant change in CI observed during either treatment. The exact reason for the lack of change in CI during dobutamine administration therefore remains unclear. It is possible that one or more of the sedative and anaesthetic agents used in this study altered the response to dobutamine administration; however, studies specifically designed to assess drug interactions are required to investigate this possibility.
The failure of co-administration of fluids (20 mL/kg bwt Hartmann's solution bolus) and dobutamine to significantly increase CI in our study contrasts with finding in other species where co-administration of fluids and vasoactive agents were more effective at increasing Qt than vasoactive agents alone [10, 26] . This may reflect differences in study design such as a different physiological state of animals prior to treatment or the use of vasopressors rather than inotropes. One study was performed in anaesthetised dogs suffering from haemorrhagic shock [10] and the other in conscious normotensive sheep [26] . It is possible that lack of effect in our study was due to the redistribution of the fluids by the time Qt was recorded. However, since [Hb] did not change and remained significantly lower during and after concurrent administration of dobutamine and fluids when compared with dobutamine alone, this explanation seems unlikely. It is also possible in our study that we failed to give a sufficient volume of fluids or possibly the cardiovascular effects of dobutamine and other sedative and anaesthetic drugs administered predominated, thus preventing any effect associated with the volume of fluids administered in our study being detected.
Interestingly, FBF significantly increased in horses during concurrent administration of fluids and dobutamine. An increase in FBF in the absence of increases in CI, has been observed in halothane-anaesthetised horses [2] and suggests that the increase in FBF seen is the result of increased perfusion pressure, decreased PVR due to dobutamine mediated b 2 receptor stimulation [27] , or a combination of both. As the targeted increase in BP observed between treatments in our study was similar, it is more likely that a difference in PVR was responsible for the differences observed across treatments. As dobutamine was administered as part of both treatments, the difference in PVR is likely the result of fluid administration altering PCV. Fluid administration could decrease PCV and thus blood viscosity, thereby reducing PVR and increasing blood flow to a greater extent than dobutamine administration alone.
In conclusion, in an experimental model of isoflurane-induced hypotension in healthy horses, although dobutamine administration alone resulted in increased DO 2 I, the co-administration of fluids and dobutamine resulted in an increase in FBF. This suggests that co-administration of fluids and dobutamine may provide a beneficial effect on muscle perfusion even without an effect on cardiac function and thus co-administration of fluids and dobutamine may be beneficial.
